Get the Stockscreener App
3.82
4.50%
-0.18
After Hours:
3.82
Briacell Therapeutics Corp stock is traded at $3.82, with a volume of 177.28K.
It is down -4.50% in the last 24 hours and down -21.88% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$4.00
Open:
$3.95
24h Volume:
177.28K
Relative Volume:
0.44
Market Cap:
$27.70M
Revenue:
-
Net Income/Loss:
$-29.01M
P/E Ratio:
-0.079
EPS:
-48.3535
Net Cash Flow:
$-29.34M
1W Performance:
-2.55%
1M Performance:
-21.88%
6M Performance:
-49.74%
1Y Performance:
+0.53%
1-Day Range:
$3.74
$3.95
1-Week Range:
$3.60
$4.03
52-Week Range:
$0.61
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.82 | 29.00M | 0 | -29.01M | -29.34M | -48.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.76 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
Street Watch: Is BriaCell Therapeutics Corp a defensive stock2025 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License - National Today
BriaCell Restructures Soluble CD80 Program via BriaPro Deal - TipRanks
BriaCell enters asset sale to BriaPro for sCD80, receives 23.97M shares and up to $3M credit - TradingView
(BCT) Investment Performance Report (BCT:CA) - Stock Traders Daily
Is BriaCell Therapeutics Corp. stock a top pick in earnings seasonJuly 2025 Catalysts & Risk Adjusted Buy and Sell Alerts - mfd.ru
Bull Run: What is BriaCell Therapeutics Corp. Equity Warrant’s valuation compared to sector2025 Geopolitical Influence & Weekly Setup with High ROI Potential - mfd.ru
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - Intellectia AI
BriaCell (BCTX) Expands Biologic Cancer Treatments Through New A - GuruFocus
BriaPro to Acquire BriaCell’s Soluble CD80 License in Strategic Cancer Immunotherapy Deal - TipRanks
BriaCell Therapeutics Brief: BriaCell and BriaPro Entering Into Asset Purchase Agreement for Exclusive Soluble CD80 License - marketscreener.com
Will BriaCell Therapeutics Corp. Equity Warrant stock maintain momentum in 2025Market Activity Report & Verified Chart Pattern Signals - mfd.ru
BriaCell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - marketscreener.com
(BCT) Technical Patterns and Signals (BCT:CA) - Stock Traders Daily
BriaCell Wins Fifth Straight Safety Nod for Fast-Track Phase 3 Breast Cancer Trial - TipRanks
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue - marketscreener.com
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study - marketscreener.com
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - The Manila Times
BriaCell Receives Positive Recommendation from Data Safety - GlobeNewswire
BriaCell Awarded New Zealand Patent for its Whole Cell Technology - Intellectia AI
Why BriaCell Therapeutics Corp. stock could be next big winnerTrade Exit Summary & High Conviction Buy Zone Alerts - mfd.ru
What is BriaCell Therapeutics Corp. Equity Warrant s debt to equity ratioJuly 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
Entry Recap: Will BriaCell Therapeutics Corp. stock go up in YEARTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru
Is now the right time to enter BriaCell Therapeutics Corp.2025 Fundamental Recap & Risk Controlled Daily Plans - mfd.ru
Will BriaCell Therapeutics Corp. Equity Warrant announce a stock splitJuly 2025 Rallies & Daily Volume Surge Signals - mfd.ru
Can BriaCell Therapeutics Corp. stock maintain growth trajectoryPrice Action & Free Low Drawdown Momentum Trade Ideas - mfd.ru
(BCT) Equity Trading Insights (BCT:CA) - Stock Traders Daily
Published on: 2026-02-14 21:45:18 - mfd.ru
Does BriaCell Therapeutics Corp. Equity Warrant have pricing powerMarket Activity Report & Technical Confirmation Alerts - mfd.ru
Will BriaCell Therapeutics Corp. Equity Warrant stock outperform value stocks2025 Winners & Losers & Community Verified Swing Trade Signals - mfd.ru
Does BriaCell Therapeutics Corp. stock have upside surprise potentialJuly 2025 Momentum & Consistent Return Strategy Ideas - mfd.ru
Is now the right time to enter BriaCell Therapeutics Corp. Equity Warrant2025 Volume Leaders & Safe Capital Growth Tips - mfd.ru
When (BCT) Moves Investors should Listen (BCT:CA) - Stock Traders Daily
(BCT) Long Term Investment Analysis (BCT:CA) - Stock Traders Daily
Published on: 2026-02-07 21:02:33 - baoquankhu1.vn
Published on: 2026-02-07 19:20:19 - baoquankhu1.vn
Market Recap: Does BriaCell Therapeutics Corp align with a passive investing strategyWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Published on: 2026-02-06 19:26:35 - baoquankhu1.vn
Published on: 2026-02-04 18:01:12 - baoquankhu1.vn
Stocks in play: BriaCell Therapeutics Corp. - Barchart.com
Big Picture: Should I buy BriaCell Therapeutics Corp Equity Warrant stock nowEarnings Recap Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
How does BriaCell Therapeutics Corp. Equity Warrant compare to its peersJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Will BriaCell Therapeutics Corp. stock hit new highs in YEAR2025 Risk Factors & AI Powered Trade Plan Recommendations - mfd.ru
What’s the profit margin of BriaCell Therapeutics Corp. Equity WarrantPortfolio Gains Summary & Weekly Top Stock Performers List - mfd.ru
BriaCell Brief: Says Patients' Images Show Regression And Resolution Of Metastasized Tumors And Immune Activation - marketscreener.com
(BCT) Equity Market Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment - GuruFocus
BriaCell Treatment Shows Significant Efficacy in Cancer Patients - Intellectia AI
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation - Sahm
Can BriaCell Therapeutics Corp. ride the EV waveJuly 2025 Pullbacks & Accurate Buy Signal Alerts - mfd.ru
BriaCell reports long-term survival data in metastatic breast cancer By Investing.com - Investing.com India
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):